Improved synthesis of unique estradiol-linked platinum(II) complexes showing potent cytocidal activity and affinity for the estrogen receptor alpha and beta

Steroids

Volumn 73, Issue 11, 2008, Pages 1077-1089

  Descôteaux, Caroline ^a   Leblanc, Valérie ^a   Bélanger, Geoffroy ^a   Parent, Sophie ^a   Asselin, Éric ^a   Bérubé, Gervais ^a  

^a UNIVERSITÉ DU QUÉBEC À TROIS RIVIÈRES   (Canada)

Author keywords

17 Estradiol linked platinum(II) complex; Biological activity; Breast cancer; Cisplatin; Estrogen receptor

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN DERIVATIVE; ESTRADIOL; ESTRADIOL PLATINUM COMPLEX; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PLATINUM COMPLEX; SEX HORMONE;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; MOLECULAR STRUCTURE; ORGANOPLATINUM COMPOUNDS; PLATINUM; SPECTROPHOTOMETRY, INFRARED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 46749149988     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2008.04.009     Document Type: Article

References (24)

1. Boulikas T., and Vougiouka M. Cisplatin and platinum drugs at the molecular level. Oncol Rep 10 (2003) 1663-1682
2. Van Zutphen, and Reedijk J. Targeting platinum anti-tumor drugs: overview of strategies employed to reduce systemic toxicity. Coor Chem Rev 249 (2005) 2845-2853
3. Wang D., and Lippard S.J. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4 (2005) 307-320
4. Hamilton S. http://www.chemocare.com/bio/cisplatin.
5. Gabano E., Cassino C., Bonetti S., Prandi C., Colangelo D., Ghiglia A., et al. Synthesis and characterisation of estrogenic carriers for cytotoxic Pt(II) fragments: biological activity of the resulting complexes. Org Biomol Chem 3 (2005) 3531-3539
6. Gagnon V., St-Germain M.E., Descôteaux C., Provencher-Mandeville J., Parent S., Mandal S.K., et al. Biological evaluation of novel estrogen-platinum(II) hybrid molecules on uterine and ovarian cancers-molecular modeling studies. Bioorg Med Chem Lett 14 (2004) 5919-5924
7. DeSombre E.R., Shafii B., Hanson R.N., Kuivanen P.C., and Hughes A. Estrogen receptor-directed radiotoxicity with Auger electrons: specificity and mean lethal dose. Cancer Res 52 (1992) 5752-5758
8. Lemieux C. Effets et mécanismes d'action d'un modulateur sélectif des récepteurs des oestrogènes sur le métabolisme des lipides. Thesis in Physiologie endocrinologie. Université Laval: Québec; 2005.
9. Tanimoto K., Eguchi H., Yoshida T., Hajiro-Nakanishi K., and Hayashi S. Regulation of estrogen receptor alpha gene mediated by promoter B responsible for its enhanced expression in human breast cancer. Nucleic Acids Res 27 (1999) 903-909
10. Ott I., and Gust R. Preclinical and clinical studies on the use of platinum complexes for breast cancer treatment. Anti-Cancer Agents Med Chem 7 (2007) 95-110
11. Spyriounis D., Demopoulos V.J., Kourounakis P.N., Kouretas D., Kortsaris A., and Antonoglou O. Estrogen-cis-dichloroethylenediamineplatinum(II) complexes: synthesis and evaluation of binding affinity for estrogen receptors and the effect on breast cancer MCF-7 cells. Eur J Med Chem 27 (1992) 301-305
12. Georgiadis M.P., and Haroutounian S.A. Synthesis and biological studies of steroid cis-platinum(II) complexes. Inorg Chim Acta 138 (1987) 249-252
13. Cassino C., Gabano E., Ravera M., Cravotto G., Palmisano A.V.G., Jaouen G., et al. Platinum(II) and technetium(I) complexes anchored to ethynylestradiol: a way to drug targeting and delivery. Inorg Chim Acta 357 (2004) 2157-2166
14. Barnes K.R., Kutikov A., and Lippard S.J. Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes. Chem Biol 11 (2004) 557-564
15. Perron V., Rabouin D., Asselin E., Parent S., C-Gaudreault R., and Bérubé G. Synthesis of 17beta-estradiol-linked platinum(II) complexes and their cytocidal activity on estrogen-dependent and -independent breast tumor cells. Bioorg Chem 33 (2005) 1-15
16. He Y., Groleau S., C-Gaudreault R., Caron M., Thérien H.M., and Bérubé G. Synthesis and in vitro biological evaluation of new triphenylethylene platinum(II) complexes. Bioorg Med Chem 5 (1995) 2217-2222
17. Perrin D.D., and Armarego W.L.F. Purification of laboratory chemicals. 3rd ed. (1988), Pergamon Press, Oxford
18. Still W.C., Kahn M., and Mitra A. Rapid chromatographic techniques for preparative separation with moderate resolution. J Org Chem 43 (1978) 2923-2925
19. Carmichael J., DeGraff W.G., Gazdar A.F., Minna J.D., and Mitchell J.B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47 (1987) 936-942
20. Eglen R.M. Enzyme fragment complementation: a flexible high throughput screening assay technology. Assay Drug Dev Technol 1 (2002) 97-104. http://www.discoverx.com/pf.php%3Fp=25 The HitHunterTM EFC estrogen receptor fluorescence assay kit and protocol, were obtained from Discoverx, Fremont, California, USA (http://www.discoverx.com/pf.php?p=25).
21. Greene T.W., and Wuts P.G.M. Protective groups in organic synthesis. 3rd ed. (2000), John Wiley & Sons, New York
22. Maiti G., Roy S.C., and Mild A. Efficient method for selective deprotection of tetrahydropyranyl ethers to alcohols. J Org Chem 61 (1996) 6038-6039
23. 13C NMR data. Steroids 62 (1997) 674-681
24. Beck M.T., Peirce S.K., and Chen W.Y. Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R. Oncogene 21 (2002) 5047-5055